Abstract
Receptor tyrosine kinases (RTK) are transmembrane receptors regulating cellular proliferation, differentiation, apoptosis, motility and recruitment of the vasculature. Aberrant expression and/or function of RTK have been detected in many malignant tumors and are considered to be a part of the transformed phenotype. The action of several classes of anti-cancer drugs is based on specific recognition of RTK. Monoclonal antibodies target extracellular binding domains, while tyrosine kinase inhibitors (TKI) bind to intracellular kinase domains to suppress RTK signaling. The issues regarding the efficient use of RTK targeting are the inter- and intra-patient heterogeneity of RTK expression and the changes of expression levels during the course of disease and in response to therapy. Radionuclide molecular imaging of RTK expression may aid in selecting patients who would benefit from RTK-targeting therapy and in identifying non-responders. Therefore, the therapy would be more personalized. Currently, radiolabeled proteins (monoclonal antibodies and their fragments, natural peptides ligands to RTK and de novo selected affinity proteins) and TKI and their analogues are under development for the visualization of RTK. In this review, we discuss the advantages and disadvantages of these approaches.
Keywords: Radionuclide, molecular imaging, receptor tyrosine kinases, monoclonal antibodies, tyrosine kinase inhibitors, scaffold proteins.
Current Pharmaceutical Design
Title:Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Volume: 20 Issue: 14
Author(s): Mohamed Altai, Anna Orlova and Vladimir Tolmachev
Affiliation:
Keywords: Radionuclide, molecular imaging, receptor tyrosine kinases, monoclonal antibodies, tyrosine kinase inhibitors, scaffold proteins.
Abstract: Receptor tyrosine kinases (RTK) are transmembrane receptors regulating cellular proliferation, differentiation, apoptosis, motility and recruitment of the vasculature. Aberrant expression and/or function of RTK have been detected in many malignant tumors and are considered to be a part of the transformed phenotype. The action of several classes of anti-cancer drugs is based on specific recognition of RTK. Monoclonal antibodies target extracellular binding domains, while tyrosine kinase inhibitors (TKI) bind to intracellular kinase domains to suppress RTK signaling. The issues regarding the efficient use of RTK targeting are the inter- and intra-patient heterogeneity of RTK expression and the changes of expression levels during the course of disease and in response to therapy. Radionuclide molecular imaging of RTK expression may aid in selecting patients who would benefit from RTK-targeting therapy and in identifying non-responders. Therefore, the therapy would be more personalized. Currently, radiolabeled proteins (monoclonal antibodies and their fragments, natural peptides ligands to RTK and de novo selected affinity proteins) and TKI and their analogues are under development for the visualization of RTK. In this review, we discuss the advantages and disadvantages of these approaches.
Export Options
About this article
Cite this article as:
Altai Mohamed, Orlova Anna and Tolmachev Vladimir, Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113196660667
DOI https://dx.doi.org/10.2174/13816128113196660667 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets Anticancer Properties of Asian Water Monitor Lizard (Varanus salvator), Python (Malayopython reticulatus) and Tortoise (Cuora kamaroma amboinensis)
Anti-Cancer Agents in Medicinal Chemistry “Legal Highs” – New Players in the Old Drama
Current Drug Abuse Reviews Berberine in the Treatment of Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Insulin, Thrombin, ERK1/2 Kinase and Vascular Smooth Muscle Cells Proliferation
Current Pharmaceutical Design Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Ability of older people with dementia or cognitive impairment to manage medicine regimens: a narrative review
Current Clinical Pharmacology Sympathetic Nervous System in Patients with Sleep Related Breathing Disorders
Current Hypertension Reviews Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs)
Current Vascular Pharmacology Biomarkers in Aortic Valve Stenosis and their Clinical Significance in Transcatheter Aortic Valve Implantation
Current Medicinal Chemistry Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Innate Inflammatory Responses in Stroke: Mechanisms and Potential Therapeutic Targets
Current Medicinal Chemistry Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Advanced Techniques for Penetration Enhancement in Transdermal Drug Delivery System
Current Drug Delivery The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry